Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Jiang

Internal Medicine Los Angeles, CA Medical Doctor

NPI 1942703723 CMS profile 7229924

650 Charles E Young Dr S, Los Angeles, CA 90095

Open in the dashboard

General payments

$52,394

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Jiang of Los Angeles, CA is reported in the CMS Open Payments database as having received $52,394 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,834 130
2024 General $7,815 47
2023 General $537 5
2022 General $181 3
2019 General $28 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Jiang
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Jiang were reported at $43,834. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Jiang Internal Medicine median Middle half National median
2019 $28 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $181 $141 $42–$496 $149
2023 $537 $149 $45–$519 $160
2024 $7,815 $154 $47–$537 $164
2025 $43,834 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $28,025 37 payments
  2. Boston Scientific Corporation $19,622 51 payments
  3. Medtronic, Inc. $3,359 71 payments
  4. Biosense Webster, Inc. $786 17 payments
  5. Biotronik Inc. $492 4 payments
  6. Lantheus Medical Imaging, Inc. $26 1 payment
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $22 1 payment
  8. Philips Electronics North America Corporation $20 1 payment
  9. Atricure, Inc. $15 1 payment
  10. Maquet Cardiovascular U.S. Sales, L.L.C. $14 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $35,000 3 payments
  2. Travel and Lodging $10,339 50 payments
  3. Food and Beverage $6,646 131 payments
  4. Education $409 2 payments
Products named General payments · program years 2019–2025
  1. ASSURITY $12,500 1 payment
  2. TACTICATH $12,500 1 payment
  3. General - Brady $10,010 2 payments
  4. INGEVITY+ $2,412 13 payments
  5. FARAPULSE $1,199 7 payments
  6. VersaCross Access Solution $1,124 7 payments
  7. ENSITE PRECISION $974 12 payments
  8. Carto 3 $761 16 payments
  9. ENSITE Structural Heart $759 9 payments
  10. ENSITE Electrophysiology $633 4 payments
  11. Other $2,420 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

96

Median for Internal Medicine: 777

Drug cost

$9,179

Median for Internal Medicine: $73,373

Branded share of claims

29.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 13 $8,744
Metoprolol Succinate Generic 14 $147
Atorvastatin Calcium Generic 24 $114
Amlodipine Besylate Generic 16 $62
Clopidogrel Clopidogrel Bisulfate Brand 15 $58
Carvedilol Generic 14 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DEFINITY
  • Lantheus Medical Imaging, Inc. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record